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Abstract
Background: Benzodiazepines are frequently prescribed to elderly patients' despite concerns
about adverse effects leading to injurious falls. Previous studies have not investigated the extent to
which patients with pre-existing risk factors for falls are prescribed benzodiazepines. The objective
of this study is to assess if some of the risk factors for falls are associated with new benzodiazepine
prescriptions in elderly persons.
Methods: Using provincial administrative databases, elderly Quebec residents were screened in
1989 for benzodiazepine use and non-users were followed for up to 5 years. Logistic regression
models were used to evaluate potential predictors of new benzodiazepine use among patient
baseline characteristics.
Results: In the 252,811 elderly patients who had no benzodiazepine prescription during the
baseline year (1989), 174,444 (69%) never filled a benzodiazepine prescription and 78,367 (31%)
filled at least one benzodiazepine prescription. In the adjusted analysis, several risk factors for falls
were associated with statistically significant increases in the risk of receiving a new benzodiazepine
prescription including the number of prescribing physicians seen at baseline (OR: 1.12; 95% CI
1.11–1.13), being female (OR: 1.20; 95% CI 1.18–1.22) or a diagnosis of arthritis (OR: 1.11; 95% CI
1.09–1.14), depression (OR: 1.42; 95% CI 1.35–1.49) or alcohol abuse (OR: 1.24; 95% CI 1.05–
1.46). The strongest predictor for starting a benzodiazepine was the use of other medications,
particularly anti-depressants (OR: 1.85; 95% CI 1.75–1.95).
Conclusion: Patients with pre-existing conditions that increase the risk of injurious falls are
significantly more likely to receive a new prescription for a benzodiazepine. The strength of the
association between previous medication use and new benzodiazepine prescriptions highlights an
important medication safety issue.
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Background
Even with a growing body of evidence, controversy still
surrounds the safety of benzodiazepine use especially for
elderly persons. [1-7] Physiological evidence suggests that
changes associated with aging make elderly people partic-
ularly sensitive to benzodiazepine side effects that have
been linked with an increased risk of injuries from falls.
[8-13] Despite these concerns, benzodiazepines continue
to be one of the most frequently prescribed medications
for elderly persons.[14] Many studies have examined the
correlates of current use of benzodiazepines in elderly
patients.[2,3,5,15,16] In contrast, very few have investi-
gated predictors of new use.[6,17,18] In the studies that
have looked at new benzodiazepine use, statistically sig-
nificant predictors have included the presence of depres-
sive symptoms, [18] anxiety, [4]other prescription
medication use, [17] recent hospitalization, [17] female
gender, [18] and older age.[6,18] However, none of these
findings were consistent across the studies partly because
different studies examined different potential predictors.
Yet to determine the true risk attached to benzodiazepine
use in elderly persons, it is important to determine if
patients with pre-existing risk factors for falls are more or
less likely to be given a new prescription for benzodi-
azepines.
The objective of this study was to assess whether elderly
persons who are at greater risk for injuries from falls are
also more likely to become new users of benzodiazepines.
Methods
Study Design and Setting
A 6 year cohort of elderly Quebec residents was assembled
through provincial administrative data starting January 1,
1989. The baseline period was 1989 with follow up
between January 1, 1990 and December 31, 1994. A two-
stage sampling process was used to assemble the study
cohort. First, a stratified random sample of 1,880 Quebec
physicians was selected from the master physician file of
the Quebec Health Insurance Program (RAMQ). Physi-
cians in active practice in 1989 who graduated from Que-
bec or foreign medical schools, and in specialties that
provide medical care for the elderly (general practitioners,
medical specialists, general surgeons, psychiatrists) were
eligible. Secondly, all the elderly patients that were seen
by these physicians between 1989 and 1994 were identi-
fied.[19] The selected physicians saw 727,295 individuals
in Quebec in those five years, which correspond to
approximately 89% of the total elderly population in the
province.
Participants
In order to have complete medication records, people
were excluded from the study if they were under the age of
66 at the beginning of the baseline period (n = 205,547),
had temporary, non-unique health insurance number (n
= 4,186); were institutionalized (n = 23,247) or died (n =
18,258) during the baseline year; were hospitalized for
the entire study period (n = 3,307); moved out of the
province during the baseline or first year of the study (n =
9,509), or lived in an isolated region where medication
would be dispensed by nursing stations (n = 697).
To compare new users of benzodiazepines with non-
users, participants were excluded if they filled a benzodi-
azepine prescription in the baseline year or if the first pre-
scription in the study period was a refill (n =
209,733).[6,20] New users were dispensed at least one
prescription during the study period for one of the eleven
benzodiazepines in the Quebec formulary between 1990
and 1994 and available in community based pharmacies
(triazolam, alprazolam, bromazepam, lorazepam,
oxazepam, temazepam, nitrazepam, clonazepam, chlo-
rdiazepoxide, diazepam, and flurazepam). Participants
for whom there was no benzodiazepine dispensed for the
entire baseline and study period were considered non-
users.
Data Sources
Data was extracted from four population health adminis-
trative databases: patient demographics, medical services,
prescription claims databases (Quebec Health Insurance
Program) and the hospitalization discharge summary
database (Quebec Ministry of Health and Welfare). All
databases were linked through an encrypted, unique
health care number for each patient. The validity of these
databases has been established previously. [21-23] The
patient demographic database provided age, sex, postal
code and date of death. The medical services database pro-
vided the type, location (e.g. inpatient, emergency room,
private office), diagnosis, treating and referring physician,
and date of all services provided on a fee-for-service basis
(95% of all services).[24] The prescription database pro-
vided the drug, dose, duration, prescribing physician, and
date of each prescription dispensed for persons aged 65
and older. The hospitalization database provided records
of all hospital discharges in Quebec including discharge
diagnoses, admission and discharge dates.
Measurement of Potential Predictors
Potential predictors of new benzodiazepine use consid-
ered in this study were limited to variables identified in at
least one published study as a risk factor for injuries from
falls in elderly persons.[9,25-40] For each patient, data
was retrieved on patient demographics, clinical and
health care use, impairments and disabilities and other
medication use. The variables included in each category
are detailed in Table 1.BMC Family Practice 2009, 10:1 http://www.biomedcentral.com/1471-2296/10/1
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Whether or not a patient had an injury during baseline
year due to a fall was recorded using previously validated
medical services and hospitalization databases.[22] The
impairments and disabilities recorded were identified
based on the International Classification of Diseases, 9th
revision (ICD-9).[41] In addition, all remaining diagnos-
tic codes were reviewed by two expert clinicians to capture
any conditions that could increase the risk of falls or inju-
ries and these were included under miscellaneous impair-
ments (Table 1). Prescriptions for drugs other than
benzodiazepines were retrieved from the prescription
database by drug identification number within American
Hospital Formulary (AHF) classes.
Depression was identified through diagnostic codes and
medication use and where both the diagnosis and the use
of anti-depressant medication were considered to be risk
factors for falls.[35,37,39] In order to separate patients
filling prescriptions for anti-depressants from those
patients with a diagnosis of depression, any patient with a
diagnosis for depression regardless of medication use was
considered to have depression. Another variable was cre-
ated to identify those patients who filled a prescription for
an anti-depressant but did not have a diagnosis of depres-
sion. Therefore, this new covariate, anti-depressant medi-
cation use, represented only those people using the
medication without a recorded diagnosis of depression.
Statistical Analyses
Frequency distributions of categorical baseline character-
istics were determined and the means and standard devi-
ations (sd) were reported for continuous variables. Chi-
square tests and student's t-tests were used to compare the
distribution of categorical and continuous variables,
respectively, between new users and non-users of benzo-
diazepines. Predictors of initiating benzodiazepine use
were evaluated using the multivariable logistic regression
analysis. Participants who did not fill a benzodiazepine
Table 1: Potential predictors for new benzodiazepine use measure during the baseline year.
Predictors Details
Patient Demographics:
Age in years Measured at baseline in years
Gender Comparing women to men.
Measures of health care use:
Prescribing Physicians Number of distinct physicians prescribing medication in baseline year.
Hospital Discharges Number of discharges in baseline year from acute care hospitals.
Charlson Co-morbidity Index[59] Adapted by Deyo et al for administrative databases[60] provided baseline measure of disease severity 
and comorbid conditions.
Diagnosis for impairments or disabilities associated with an increase risk for falls:
Previous Injuries from Falls Any fracture or soft tissue injury including fracture of the hip, upper extremity fractures, lower 
extremity fractures requiring medical treatment in the baseline year.
Visual Impairment ICD-9: 360–379
Arthritis ICD9: 274, 710 to 725–730, 733
Stroke ICD-9: 430–438
Depression ICD-9: 311, 298.0, 296.2, 296.3, 309.1, 300.0–300.4
Neurological Disorders Including dementia and Parkinson's disease: ICD-9: 290, 294, 331 to 337, 340–342, 344
Seizure Disorders Including epilepsy: ICD-9: 345, 780.3
Osteoporosis ICD-9: 733.0, 731.0
Misc. Impairments any other conditions not included in other categories that could increase the risk of falls or injuries 
(i.e. sprained knee)
Alcohol Abuse and/or dependence: ICD-9: 303, 291, 305.0, 535.3, 571.0–571.3, 265.2,425.5
Drug Abuse and/or dependence: ICD-9: 304, 305.1–305.9, 292
Non-benzodiazepine medication protective of fractures:
Thiazide Diuretics & Estrogen AHF: 40:28:00; 40:28:10; 68:12:00; 68:16:00
Non-benzodiazepine medication associated with an increase risk of falls:
Anti-Depressants AHF: 28:16:04
Anti-Psychotics AHF: 28:16:08
Sedatives AHF: 28:24:92
Miscellaneous Psychotropics AHF: 28:28:00 (lithium, l-tryptophan)
Non-benzodiazepine medications known to alter motor stability:
Cardiac Drugs AHF: 24:04:00
Anti-Hypertensives AHF: 24:08:00
Vasodilators AHF: 24:12:00
Opioid Agonists AHF: 28:08:08
Mixed Partial Opioid Agonists/Antagonists AHF: 28:08:12BMC Family Practice 2009, 10:1 http://www.biomedcentral.com/1471-2296/10/1
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prescription during the follow-up were censored at the
time of death, if they moved out of the province, were
admitted to a long-term institution; or the end of the
study on December 31, 1994. Statistical analyses were
conducted using SAS Systems 9.0 [42] and S-Plus 4.[43]
Ethics approval for the study was provided by the McGill
Faculty of Medicine Institutional Review Board and the
Quebec Commission for Access to Information (CAI). As
all information provided to the research team was de-
identified, the need for written informed consent by indi-
viduals was waived by the CAI.
Results
The average age of the cohort at the baseline was 73.4
years (sd = 6.0) and 52% were women. Of the final study
cohort of 252,811 elderly patients who had no benzodi-
azepine prescription during the baseline year (1989),
174,444 (69%) never filled a benzodiazepine prescription
and 78,367 (31%) went on to fill a benzodiazepine pre-
scription over the next five years.
Table 2 compares the baseline characteristics among ben-
zodiazepine non-users and new users. All differences
between groups were statistically significant (p ≤ 0.01)
except for the mean number of hospital discharges, his-
tory of injuries from falls, stroke, neurological disorders
and seizure disorders. Women were more likely to receive
a benzodiazepine prescription (55.7% of new users versus
50.9% of non-users). Overall, new users of benzodi-
azepines were more likely to be taking other medications.
New users had almost a two-fold increase in use of anti-
depressants and sedatives as well as a higher proportion of
use of cardiac medications than non-users. One of the
Table 2: Frequency or means (standard deviations) of baseline (1989) characteristics among non-users and new users of 
benzodiazepines among Quebec elderly.
Variable Frequency or Mean (s.d.) Odds Ratios and 95% Confidence 
Interval1
Non-Users n = 174,444 New Users n = 78,367
Patients Demographics
Age (in years) 73.6 (6.1) 73.0 (5.7) 0.90 (0.89–0.91)2
Women 50.1% 55.7% 1.20 (1.18–1.22)
Measures of Health Care Use
Number of Prescribing Physicians 1.8 (1.5) 2.1 (1.6) 1.12 (1.11–1.13)
Number of Acute-Care Hospital Discharges 0.2 (0.6) 0.2 (0.5) 0.93 (0.91–0.95)
Charlson Co-morbidity Index 0.5 (1.2) 0.5 (1.2) 0.98 (0.98–0.99)
Diagnosis for impairments or disabilities associated with an increase risk for falls:
Previous Injury from a Fall 4.6% 4.6% 0.93 (0.89–0.97)
Visual Impairment 21.6% 22.7% 0.98 (0.96–1.01)
Arthritis 14.2% 17.2% 1.11 (1.09–1.14)
Stroke 3.0% 2.7% 0.91 (0.86–0.96)
Depression 2.3% 3.6% 1.42 (1.35–1.49)
Neurological Disorders 2.8% 2.9% 0.95 (0.91–1.01)
Seizure Disorders 1.8% 1.8% 0.91 (0.85–0.97)
Osteoporosis 0.5% 0.5% 1.00 (0.88–1.12)
Miscellaneous Impairments 4.1% 4.6% 1.01 (0.97–1.06)
Alcohol Abuse/Dependence 0.3% 0.3% 1.24 (1.05–1.46)
Drug Abuse/Dependence 0.2% 0.2% 1.18 (0.99–1.42)
Non-benzodiazepine medication protective of fractures:
Thiazide Diuretics & Estrogens 20.6% 23.3% 1.05 (1.03–1.08)
Non-benzodiazepine medication associated with an increase risk of falls:
Anti-Depressants 2.1% 4.4% 1.85 (1.75–1.95)
Anti-Psychotics 1.3% 1.7% 1.11 (1.03–1.19)
Sedatives 2.6% 4.2% 1.37 (1.31–1.44)
Other Psychotropics 0.1% 0.2% 1.39 (1.14–1.71)
Non-benzodiazepine medications known to alter motor stability:
Cardiac Drugs 26.1% 30.2% 1.04 (1.02–1.06)
Anti-Hypertensives 12.0% 13.9% 1.06 (1.03–1.09)
Vasodilators 12.8% 16.5% 1.21 (1.18–1.24)
Opioid Agonists 0.6% 0.8% 1.11 (1.01–1.23)
Mixed Partial Opioid Agonists/Antagonists 10.8% 12.1% 1.02 (0.99–1.05)
1 Adjusted for all other potential predictors in multivariable logistic regression model.
2 Odds ratio per 5 year increase in age.BMC Family Practice 2009, 10:1 http://www.biomedcentral.com/1471-2296/10/1
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most marked differences was for filling at least one pre-
scription for another psychotropic medication during the
baseline year (8.8% of new users versus 5.3% of non-
users). Also, 41.3% of new benzodiazepine users filled at
least one prescription for medications that affect motor
stability compared to 35.6% of non-users. New users were
also more likely to have depression and arthritis than
non-users of benzodiazepines (Table 2).
A statistically significant (p < .0001) higher proportion of
elderly patients with at least one of the risk factors based
on health care use, morbidities and medication use were
prescribed a benzodiazepine (32.2% of new users versus
26.1% of non-users). The last column of Table 2 summa-
rizes the results of the multivariable logistic regression
analyses. In this analysis that adjusted for all the predic-
tors, several risk factors for falls were associated with sta-
tistically significant increases in the risk of being started
on a benzodiazepine. For example, statistically significant
predictors included the number of prescribing physicians
seen at baseline, being female or a diagnosis of arthritis,
depression or alcohol abuse (Table 2). With each addi-
tional prescribing physician seen in the baseline period,
the risk of starting a benzodiazepine increased by 12%
(Table 2). The strongest predictor for starting a benzodi-
azepine was the use of other medications, particularly
anti-depressants. Several risk factors for falls were associ-
ated with decreased likelihood of being prescribed a ben-
zodiazepine. These include older age, having a higher
number of acute-care hospital stays, having an injury from
a fall that required medical attention, or a diagnosis for
stroke or seizure disorders (Table 2).
Discussion
By assessing baseline characteristics of a large cohort of
elderly patient who did not use benzodiazepines for at
least one year, we were able to determine that many of the
pre-existing risk factors for injuries from falls significantly
increased the probability of initiating benzodiazepine
treatment.
Although many of the more recent studies that examine
the risks associated with benzodiazepine use attempt to
control for medication use and health status in elderly
persons, [9-12,32] few of these studies measured health
care utilization. In our study, one of the important predic-
tors of subsequent benzodiazepine use was the number of
prescribing physicians in the baseline year. The interpreta-
tion of this association is not straightforward. While the
estimate is adjusted for the use of many medications, and
illnesses that are associated with falls, our list of predictors
was not exhaustive. The number of prescribing physicians
may have been an indication of other aspects of health
status, not reflected by the variables included in our anal-
yses. For example, we were unable to comprehensively
capture mental health problems and these elderly patients
are known to have higher rates of physician visits.[44,45]
On the other hand, this predictor may also have been a
measure of an individual patient's tendency to higher uti-
lization of the health care system, independent of the
patient's actual health status. Within the context of a data-
base study, it is impossible to make this distinction but
the conjecture that this association may have partly
reflected a propensity to visit doctors was supported by
the fact that the association persisted even after adjusting
for several measures of the patient's health status. This was
consistent with the previous finding that the risk of poten-
tially inappropriate drug combinations increased with
number of physicians involved in the medical manage-
ment of an elderly patient.[46]
The association between the increased number of pre-
scribing physicians and the risk of receiving potentially
inappropriate prescriptions raises an important patient
safety concern. [46-48] One strong trend demonstrated in
our study is the increased risk of receiving a benzodi-
azepine after receiving a prescription for an anti-psychotic
or psychotropic. As indicated by Avorn and Shrank in a
recent publication, adverse drug reactions in elderly
patients are a substantial cause of preventable illness.[49]
The authors point out that an adverse drug reaction in an
elderly person may be mistakenly attributed by the
patient or the physician to an emerging disease or the age-
ing process itself due to a belief that aging is associated
with inherent and inevitable disability.[49] Although
many depressed elderly persons suffer from anxiety and
insomnia that may be treated with a benzodiazepine,
antipsychotics and other psychoactive medications may
produce depression like symptoms. The subsequent use of
benzodiazepines after receiving a prescription for these
medications may indicate that physicians are treating a
reversible adverse effect with a benzodiazepine starting a
medication "cascade" rather than reducing the dose or
discontinuing the problematic medication. At the very
least, the fact that the previous use of these medications is
associated with an increased risk of receiving a benzodi-
azepine may result in the exacerbation of any existing
iatrogenic illness. This requires further investigation as an
adverse effect is one of the few conditions in elderly
patients where a complete "cure" can be expected. [44,49]
Despite the obvious lack of some details on the patients'
health status, the use of administrative databases in our
study offered several advantages. The main advantage was
in sample size resulting in high statistical power for
hypothesis testing and precision of the estimation. One of
the limitations, common for pharmacoepidemiologic
studies using information from administrative health
databases, was that filling a prescription was only a proxy
for actual benzodiazepine use.[50] Since there is evidenceBMC Family Practice 2009, 10:1 http://www.biomedcentral.com/1471-2296/10/1
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that physicians often prescribe benzodiazepines on an "as
needed" basis and that elderly patients often show poor
compliance in taking their medication, database records
may overestimate the actual use of benzodi-
azepines.[51,52] However, this problem does not affect
our results as we assess the predictors of receiving a new
benzodiazepine prescription rather than the effects of the
consumption of a benzodiazepine. Although our data is
based on information from the early to mid 1990s, recent
research indicates that benzodiazepine prescribing has
not diminished, making our findings relevant to the cur-
rent state of health care.[53,54]
Another problem that occurs with database studies and
chart reviews, is the under-diagnosis and under-reporting
of the treatment of certain diseases.[55] This likely limited
our ability to examine the association between pre-exist-
ing osteoporosis and subsequent new benzodiazepine
use. The low frequency of detected osteoporosis diag-
noses, likely due to under-reporting, did not allow us to
explore the role of this factor as a predictor. Also, certain
conditions such as anxiety and insomnia were often not
coded in the medical services billing database making it
difficult to assess the association between these diagnoses
and benzodiazepine use.[56]
Furthermore, there was no prescription information avail-
able during hospitalization. Although we adjusted our
estimates by removing periods of hospitalization from the
total period when a patient was at risk of receiving a ben-
zodiazepine, the lack of this information may have
accounted for the apparent protective effect of the number
of acute care hospital stays in the baseline on subsequent
new benzodiazepine use. Grad et al (1999) found that
recent hospitalization increases the risk of new benzodi-
azepine use following discharge in community-dwelling
elderly residents of Quebec.[17]
Our findings also have important implications for
research on the adverse effects of benzodiazepine. Many
of the risk factors for falls meet the classic criteria for con-
founders as they are statistically significantly associated
with benzodiazepine use which is also a risk factor for
falls.[57] This emphasizes the need to adjust for these fac-
tors in any study that evaluates adverse effects associated
with benzodiazepine use.
Conclusion
Evidence from our study does indicate that physicians are
less likely to prescribe to elderly patients with certain risk
factors for falls such more elderly patients, patients with a
previous injury from a fall and patients diagnosed with a
stroke or a seizure disorder. This concordance with evi-
dence based recommendations is encouraging.[58] How-
ever, it is apparent from our results that benzodiazepines
are a commonly used medication among elderly persons,
even among those with other pre-existing conditions that
strongly increase their risk of injuries from falls, particu-
larly the use of other medications. This highlights an
important medication safety issue.
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